Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Henry Schein (HSIC)

Tipranks - Wed Feb 25, 2:12PM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Elanco Animal Health (ELANResearch Report) and Henry Schein (HSICResearch Report).

Claim 50% Off TipRanks Premium

Elanco Animal Health (ELAN)

Leerink Partners analyst Daniel Clark reiterated a Buy rating on Elanco Animal Health today and set a price target of $30.00. The company’s shares closed last Tuesday at $25.73.

Clark has an average return of 46.3% when recommending Elanco Animal Health. ;'>

According to TipRanks.com, Clark is ranked #3225 out of 12136 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Elanco Animal Health with a $27.60 average price target, representing a 14.7% upside. In a report issued on February 16, Bank of America Securities also maintained a Buy rating on the stock with a $28.00 price target.

See today’s best-performing stocks on TipRanks >>

Henry Schein (HSIC)

In a report released today, Michael Cherny from Leerink Partners reiterated a Hold rating on Henry Schein, with a price target of $87.00. The company’s shares closed last Tuesday at $83.80.

According to TipRanks.com, Cherny is a 4-star analyst with an average return of 4.8% and a 56.0% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Medline, Inc. Class A, Hims & Hers Health, and Envista Holdings. ;'>

Currently, the analyst consensus on Henry Schein is a Moderate Buy with an average price target of $88.50, which is a 5.4% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.